
ProJenX Reports Positive Safety Data for ALS Drug Prosetin
Forty-one patients with amyotrophic lateral sclerosis have completed the multiple ascending dose portion of the PRO-101 study, providing the first clinical evidence that prosetin is safe, well-tolerated, and capable of achieving target engagement at therapeutic levels in the central nervous system.
























